|
|
Post by kc on Feb 14, 2016 16:53:14 GMT -5
Could Novartis be the perfect buyer / Partner for MannKind?
they are focused in finding cures beyond the typical insulin injections. They have partnered with JDRF like MannKind has in the past. Perhaps this might be a good fit. NVS is looking beyond insulin injections.
They are focused on cell regeneration as a cure or solution. This is the point that Both Edelman and Al Mann has made about Afrezza giving the Pancreas a break. Seems that there might be something good that both companies have the same goals and Novartis has the clout to make Afrezza a winning blockbuster drug. They seem to maybe compliment what MannKind brings to the table.
search for this story:
www.novartis.com/stories/discovery/stepping-toward-regenerative-medicine-diabetes
|
|
|
|
Post by peppy on Feb 14, 2016 18:26:31 GMT -5
|
|
|
|
Post by kc on Feb 14, 2016 19:48:54 GMT -5
I know we have had a thread on JDRF and Cell regeneration that involved research by perhaps Samsun,Edelman and others.
Heck even the MIA Spiro had a thread on it.
Spiro on
mnkd.proboards.com/thread/2004/pancreatic-beta-cell-regeneration
But somewhere Al or somebody talked about Afrezza Mimics Normal Function of the Pancreas. That is the Holy Grail of diabetes treatment if we can find the link using Afrezza to assist with Pancreatic cell regeneration.
Wish that I could find that thread, it but I know the super sleuths on this board will find that detail.
|
|
|
|
Post by peppy on Feb 14, 2016 20:39:25 GMT -5
I know we have had a thread on JDRF and Cell regeneration that involved research by perhaps Samsun,Edelman and others.
Heck even the MIA Spiro had a thread on it.
Spiro on
mnkd.proboards.com/thread/2004/pancreatic-beta-cell-regeneration
But somewhere Al or somebody talked about Afrezza Mimics Normal Function of the Pancreas. That is the Holy Grail of diabetes treatment if we can find the link using Afrezza to assist with Pancreatic cell regeneration.
Wish that I could find that thread, it but I know the super sleuths on this board will find that detail.
I think that video may be on you tube. |
|
|
|
Post by peppy on Feb 14, 2016 20:43:38 GMT -5
regarding Novartis and technosphere. reading through the Mannkind patents for technosphere, the immunology patents would suggest technosphere is a delivery system for vaccines. Here we present the Top 5 vaccine companies based on their 2012 vaccine revenues, screencast.com/t/cvS8c3STf7v |
|
|
|
Post by kc on Feb 14, 2016 21:22:46 GMT -5
Searching for information on Novartis it seems that they have been working with a firm by the name of Pond Healthcare on a Spirometer for a sale price of $24.00 USD. Now that device is geared toward the Asthma patient it perhaps might work for a Doctor needing to administer a inexpensive test in his office for Afrezza.
How about a Spirometer that would be developed for use by a Doctor at a cost under $50.00 Is that possible? It looks like Novartis has been working with a firm named pond to just do exactly that. You can search for it but their goal is to have one for under 200 SEK which equals about $24.00 USD. Again it might take awhile for use in the USA but not for other markets.
How powerful would it be for MannKind to be able to include this in a Sample Patient Kit for the Doctor to use with the patient in his office. The Doctor keeps the disposable Spirometer and the Patient gets the 30 day Afrezza sample kit.
More on Pond:
We’ve been working a lot with medical care solutions, which we are really happy to do. But while doing it, we couldn’t escape one itching insight: Many devices used to analyze and help people suffering from various conditions are way to expensive – and therefore not very accessible to the people that need them.
Gear for asthma patients was one category suffering from severe expensivitis. For example, spirometers used to keep track of how sick one is and how much meds you need are often about 2000-7000 SEK. We wanted to create one that was below 200 SEK.
Through desktop research combined with expert interviews, analyzing existing devices and lots more we came up with a number of routes that we explored further. We sketched out a number of different versions of our ideas – and finally came up with a viable solution.
We started looking around for partners, and found one in Novartis, a global medical company, and then started developing a working prototype.
The prototype has been presented to over 400 physicians who have given us elaborate feedback – and now, the next step is going into production. Still with the goal to keep it below the magic 200 SEK limit.
Search this term below:
www.healthcareinnovation.se/case/breathing-new-air-into-health-checkups/
Client: Novartis Service: Innovation
|
|
|
|
Post by kc on Feb 14, 2016 22:00:18 GMT -5
I hope that Matt and the MannKind board read Proboards.
another image of the Pond Spirometer. This would be great if it actually came to market quickly. But I would not hold my breath as it might take years to get FDA approval of such an economical spirometer. $24.00... What a deal.
pondsthlm.com/case/cutting-costs-for-those-that-need-it-the-most/
|
|
|
|
Post by kc on Feb 14, 2016 23:21:39 GMT -5
Check this out. This is already approved by European regulators with the CE-Certified. This article was from December 2015. it also mentions a US Firm working on the same type of device. (Cohero Health). Again it would be great if MannKind could provide as part of the Doctor Sample Kit this simple Spirometer for Doctor use only. Makes it easy and economical if the cost is about $24.00 each then it would be a nominal cost for MannKind to include in the Doctor kit. Doctor uses the Spirometer and then gives the Patient the 30 day Afrezza Sample Pack with the 800 number to the Afrezza specialist to give the patient information on how to use the product properly.
medcitynews.com/2015/12/swedish-design-firm-pond-healthcare-collaborates-with-novartis-on-smart-spirometer/
Health IT, Pharma
Swedish design firm Pond Healthcare collaborates with Novartis on smart spirometer
By Stephanie Baum
Dec 4, 2015 at 2:39 PM
pond novartis air spirometerSwedish design firm Pond Healthcare Innovation has developed apps for pharmaceutical companies focusing on the European market supporting patients and clinicians. It developed a symptom tracker to support multiple sclerosis patients for Novartis and a training tool for physicians on Hyponatremia for Otsuka. Its latest collaboration with Novartis is a smart spirometer and companion app designed to evaluate lung function.
The goal of these devices is to get a regular assessment of lung function so if there is a sudden change, physicians can intervene faster and reduce the need for hospitalization.
Pond Healthcare Innovation CEO Daniel Taub said in an interview that the Air Smart spirometer device is CE-certified by European regulators and is available in Europe. Taub said that it collaborated with Novartis’s on a COPD application for the device, but he believes it could be applied to a broader variety of respiratory conditions beyond Europe.
It plans to launch a version of the smartphone-enabled device for Android users in the first quarter of 2016. The company is also working on an application to diagnose asthma.
It reflects a broader Beyond the Pill collaboration trend between pharma and digital health companies to add services and connected devices to improve patient outcomes. Cohero Health developed a smart spirometer for the U.S. market for people with respiratory problems.
Novartis did not immediately respond to a request for comment before this post was published.
Here is a link from Vimeo on the
|
|
|
|
Post by blindhog1 on Feb 14, 2016 23:36:14 GMT -5
Peppy, as you know I'm in a 5 year study with Novartis. It's for old cardiac cripples that also have diabetes. I have been getting a lot of attention recently with my numbers since I've been taking Afrezza. Since I don't have a CGM I keep daily records. At first I submitted copies monthly. After awhile they asked for the originals instead of copies. Fortunately I kept all these notes because of Afrezza and my ENDO...I could have cared less about Novartis. No one wants to talk to me but my numbers are real...and they know it.  |
|
|
|
Post by kc on Feb 14, 2016 23:41:52 GMT -5
information on
Cohero Health gets FDA clearance for smartphone-connected spirometer comparable accuracy to clinical-grade spirometers
mobihealthnews.com/44023/cohero-health-gets-fda-clearance-for-smartphone-connected-spirometer
Cohero Health gets FDA clearance for smartphone-connected spirometer
By Jonah Comstock
June 02, 2015
Cohero spirometerNew York City-based Cohero Health has received FDA 510(k) clearance for its mobile connected spirometer. The Bluetooth-connected device measures critical lung function with comparable accuracy to clinical-grade spirometers, and sends the data to a smartphone or tablet.
Cohero Health has already been using the spirometer as part of its medication adherence tracking platform in a pilot at Mount Sinai Medical Center. By using both a spirometer and an inhaler sensor, Cohero is able to not only track inhaler usage, but make connections between inhaler usage and lung function.
“Because we track the use of the controller medication, we can also track the use of the rescue inhaler and track the resulting changes in lung function,” cofounder and COO Daniel Weinstein told MobiHealthNews last fall. “By combining those three things we can do some really cool predictive analytics. From the patient-specific standpoint we can tell this patient’s headed for an adverse event, or we can say ‘Hey this patient has been taking his medicine the way he’s supposed to, but he’s not getting better. Maybe the doctor needs to change the prescription.’ We can also do some cool macro level things, we can track [whether] certain sub-populations do better or worse on a particular drug, and that’s useful for pharma. So we’ve gotten a lot of interest from pharma to monitor patient populations on their product.”
Specifically, the spirometer allows users to track their lung function at home, not just in clinic, with more accuracy than a peak-flow meter, which is currently the standard of care for at-home lung function monitoring. And while the peak-flow meter only tracks maximum speed of exhalation, the spirometer tracks Forced Vital Capacity (FVC) and Forced Expiratory Volume (FEV1), the speed and volume of breath over time.
Cohero Health’s newly cleared device connects to the company's pediatric and adult mobile applications, AsthmaHero and BreatheSmart respectively, to log and provide feedback on results. Both applications also deliver customized medication reminders to patients, and track use of both maintenance and rescue medication via inhaler sensors. The company's software then tracks and analyzes the effects of maintenance and rescue medication use, along with external triggers, on lung function.
The company says early pilot results have shown a 250 percent increase in medication adherence, and 100 percent reduction in hospitalizations. Cohero Health plans to launch additional pilots ahead of full commercial launch of their full platform later this year.
Tags:
Cohero Health, CoheroHealth, FDA, FDA 510(k) clearance, mobile connected spirometer, spirometer
|
|
|
|
Post by suebeeee1 on Feb 15, 2016 11:23:54 GMT -5
Searching for information on Novartis it seems that they have been working with a firm by the name of Pond Healthcare on a Spirometer for a sale price of $24.00 USD. Now that device is geared toward the Asthma patient it perhaps might work for a Doctor needing to administer a inexpensive test in his office for Afrezza.
How about a Spirometer that would be developed for use by a Doctor at a cost under $50.00 Is that possible? It looks like Novartis has been working with a firm named pond to just do exactly that. You can search for it but their goal is to have one for under 200 SEK which equals about $24.00 USD. Again it might take awhile for use in the USA but not for other markets.
How powerful would it be for MannKind to be able to include this in a Sample Patient Kit for the Doctor to use with the patient in his office. The Doctor keeps the disposable Spirometer and the Patient gets the 30 day Afrezza sample kit.
More on Pond:
We’ve been working a lot with medical care solutions, which we are really happy to do. But while doing it, we couldn’t escape one itching insight: Many devices used to analyze and help people suffering from various conditions are way to expensive – and therefore not very accessible to the people that need them.
Gear for asthma patients was one category suffering from severe expensivitis. For example, spirometers used to keep track of how sick one is and how much meds you need are often about 2000-7000 SEK. We wanted to create one that was below 200 SEK.
Through desktop research combined with expert interviews, analyzing existing devices and lots more we came up with a number of routes that we explored further. We sketched out a number of different versions of our ideas – and finally came up with a viable solution.
We started looking around for partners, and found one in Novartis, a global medical company, and then started developing a working prototype.
The prototype has been presented to over 400 physicians who have given us elaborate feedback – and now, the next step is going into production. Still with the goal to keep it below the magic 200 SEK limit.
Search this term below:
www.healthcareinnovation.se/case/breathing-new-air-into-health-checkups/
Client: Novartis Service: Innovation
Sorry, but by the time it is imported into the US and the FDA makes it conduct trials and then after everyone else has their hand out, it will cost thousands of dollars. |
|
|
|
Post by kc on Feb 15, 2016 13:20:11 GMT -5
|
|
|
|
Post by matt on Feb 15, 2016 15:59:45 GMT -5
Spirometers have been around nearly forever, which means that this device should qualify for a 510(k) registration as a Class II medical device. While the FDA will likely ask a lot of questions, they can probably get this approved without trials.
|
|
|
|
Post by mindovermatter on Feb 15, 2016 16:05:49 GMT -5
Could Novartis be the perfect buyer / Partner for MannKind?
they are focused in finding cures beyond the typical insulin injections. They have partnered with JDRF like MannKind has in the past. Perhaps this might be a good fit. NVS is looking beyond insulin injections.
They are focused on cell regeneration as a cure or solution. This is the point that Both Edelman and Al Mann has made about Afrezza giving the Pancreas a break. Seems that there might be something good that both companies have the same goals and Novartis has the clout to make Afrezza a winning blockbuster drug. They seem to maybe compliment what MannKind brings to the table.
search for this story:
www.novartis.com/stories/discovery/stepping-toward-regenerative-medicine-diabetes
I am sure MNKD management said the same thing the day Sanofi dumped Afrezza. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 15, 2016 17:46:46 GMT -5
Peppy, as you know I'm in a 5 year study with Novartis. It's for old cardiac cripples that also have diabetes. I have been getting a lot of attention recently with my numbers since I've been taking Afrezza. Since I don't have a CGM I keep daily records. At first I submitted copies monthly. After awhile they asked for the originals instead of copies. Fortunately I kept all these notes because of Afrezza and my ENDO...I could have cared less about Novartis. No one wants to talk to me but my numbers are real...and they know it. Can you please give more details on what exactly the study is? getting on afrezza and having normalized blood sugars is doing wonders.. Jackie reported her eyevision and retinopathy is improved, some one else reported their cholesterol numbers have become better and another is off their heart meds.... |
|
